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1.0±0.8 g/day (Po0.001). There was no significant differ-
ence in the systolic blood pressure between the two groups
before and after the study (P¼ 0.447). Neither was there a
difference in the diastolic blood pressure (P¼ 0.159). The
decrease in the estimated glomerular filtration rate (eGFR)
was 3.5 ml/min/year for the losartan 100 mg group compared
to 0.7 ml/min/year for the losartan 200 mg group
(Po0.0005) and there were significantly less patients with
chronic kidney disease (CKD) 4 and 5 in the losartan 200 mg
group compared to the 100 mg group (Po0.005) at the end
of 6 years.
From our experience, dose for dose, losartan is probably
equipotent to telmisartan, that is if prescribed in the dose of
losartan 150 mg versus telmisartan 80 mg. Telmisartan,
because of its longer half-life in terms of blood pressure
control3 has the advantage of offering better renoprotection
in hypertensive CKD patients (whether diabetic or IgA
nephropathy). But for patients who do not have hypertension
associated with CKD, losartan may be more appropriate as it
is a relatively weaker hypotensive drug4 and one can prescribe
larger doses without the side effects of giddiness and
hypotension. In the long term, what is of paramount
importance is preservation of renal function and prevention
of renal failure. In this respect, data for telmisartan 80 mg5
and our own studies on losartan 200 mg2 have shown that
after 5 years therapy there is a gain in eGFR for both of these
drugs which has yet to be demonstrated by other angio-
tension receptor blocker (ARBs) or angiotension converting
enzyme inhibitor (ACEI).
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We read with interest your letter in response to our trial.
We very much appreciate the issue of dose equivalence
between losartan and telmisartan. There are clearly
differences between these two agents with regard to AT1
receptor binding at the doses we used.1,2 The doses
selected, however, resulted from those most commonly
used in the United States. They are also the maximum
approved doses by the Food and Drug Administration. The
dose escalation of losartan and results on proteinuria
reduction mirror those seen with other angiotensin
receptor blocker (ARBs). Dose escalation studies with
candesartan have also shown similar findings on protei-
nuria without substantial additional blood pressure
reductions.3,4 Thus, we appreciate your observations and
do not find them surprising. It is clear that increasing ARB
dose above the current guideline recommendations to
reduce proteinuria further is warranted; this should also
be considered by regulatory agencies. The one interesting
finding in the study was that the decline in estimated
glomerular filtration rate (eGFR) was less at the higher
dose. This is important and needs confirmation in longer-
term studies.
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To the Editor: We read with interest the commentary by
Costacou and Orchard1 on the hypothesis that elevated
adiponectin levels may occur as a protective response to
vascular damage. Although such changes may be operative in
CKD, we believe that the putative involvement of adiponectin
in the process of protein-energy wasting also needs
consideration. As adiponectin is produced in inverse
proportion to fat mass, wasted patients who have lost body
weight would, as a consequence, have higher plasma
adiponectin values.2 Thus, it is not unexpected that
adjustment for body mass index resulted in the loss of
impact on mortality by adiponectin in patients with chronic
heart failure.3 Also, a nested case–control study showed that
adiponectin reflects the degree of systemic wasting that
precedes death.4 On the other hand, as intracerebroventri-
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cular administration of adiponectin in mice decreased body
weight by stimulating energy expenditure, adiponectin may
also promote wasting.5 Interestingly, high, but not low,
molecular weight adiponectin has been associated with
increased energy expenditure in CKD.6 Because to date it is
unknown if dialysis alters the proportion of the different
adiponectin isoforms, we cannot speculate on the possibility
of a uremic accumulation of high molecular weight
adiponectin. In any case, in the context of CKD, elevated
adiponectin may be confounded by, or alternatively, act as an
inducer of protein-energy wasting. Thus, future epidemiolo-
gical studies should take into account this potentially
malevolent ‘Mr Hyde side’ of adiponectin.
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We thank Carrero et al.1 for their thoughtful comments
and for bringing up an important issue. Indeed, adipo-
nectin’s involvement in protein-energy wasting may be
both possible and perhaps a constituent of this ‘paradox’.
However, we failed to observe differences in body mass
index between those who progressed to renal function
decline (o30 ml/min per 1.73 m2) and those who did not
progress among the 108 participants of the Epidemiology
of Diabetes Complications Study with a diagnosis of type 1
diabetes and overt nephropathy at study entry. Thus, the
elevation in adiponectin concentration in progressors
throughout the 16-year follow-up period was not accom-
panied by differences in body mass index in this
population. It should be noted here that these data were
based on a small subsample of the Epidemiology of
Diabetes Complications cohort and need to be replicated
in larger samples. Nevertheless, they and Dr Carrero’s
observations add more complexity to an already intricate
issue, reminding us that there is probably quite a bit more
to be learned regarding this adipokine.
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